The expert advisory panel for the Food and Drug Administration (FDA) unanimously voted Wednesday in favor of selecting the JN.1 COVID-19 subvariant to be targeted by the next round of COVID-19 vaccines this fall. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) was asked if it would recommended a monovalent vaccine that targets the JN.1 omicron subvariant for the 2024-2024 COVID vaccines. All 16 voting members voted in favor of selecting this lineage for the fall. The JN.1 subvariant is no longer the dominant COVID-19 strain in the U.S., with the most recent surveillance data indicating it makes up less than 10 percent of cases. Current projections est
Hence then, the article about fda panel picks jn 1 subvariant for fall covid vaccines was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( FDA panel picks JN.1 subvariant for fall COVID vaccines )